Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions

Experimental and Molecular Pathology

Volumn 83, Issue 2, 2007, Pages 188-197

  Rivenbark, Ashley G ^a   Livasy, Chad A ^a   Boyd, Courtney E ^a   Keppler, Daniel ^b   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Cystatin M; Metastasis; Methylation

Indexed keywords

CYSTATIN; CYSTATIN M; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; PAPILLARY CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SIGNET RING CARCINOMA; SOLID TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; CYSTATINS; DNA METHYLATION; EPITHELIAL CELLS; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 34548249665     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2007.03.008     Document Type: Article

References (35)

1. Ai L., et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 66 (2006) 7899-7909
2. Buck M., et al. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282 (1992) 273-278
3. Cromer A., et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23 (2004) 2484-2498
4. Deng G., et al. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res. 64 (2004) 2692-2698
5. Douglas D.B., et al. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res. 64 (2004) 1611-1620
6. Frosch B., et al. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 107 (1999) 28-37
7. Kane S., and Gottesman M. The role of cathepsin L in malignant transfromation. Semin. Cancer Biol. 1 (1990) 127-136
8. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett. 235 (2006) 159-176
9. Kim T.Y., et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 66 (2006) 7490-7501
10. Kos J., et al. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 15 (2000) 84-89
11. Lah T., and Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379 (1998) 125-130
12. Lau R., et al. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int. J. Oncol. 18 (2001) 17-23
13. Maciewicz R.A., et al. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett. 269 (1990) 189-193
14. Mai J., et al. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 383 (2002) 1407-1413
15. Mirza A.N., et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann. Surg. 235 (2002) 10-26
16. Muller V., et al. Sentinel lymph node dissection and micrometastasis detection in bone marrow and lymph nodes. In: Ross J.S., and Hortobagyi G.N. (Eds). Molecular Oncology of Breast Cancer (2005), Jones and Bartlett, Boston 117-127
17. Ni J., et al. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J. Biol. Chem. 272 (1997) 10853-10858
18. Prendergast G.C., and Ziff E.B. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251 (1991) 186-189
19. Reed W., et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88 (2000) 804-813
20. Rivenbark A.G., et al. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab. Invest. 86 (2006) 1233-1242
21. Rivenbark A.G., et al. DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 1 (2006) 32-44
22. Roshy S., et al. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 22 (2003) 271-286
23. Schagdarsurengin U., et al. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 26 (2006) 3089-3094
24. Shridhar R., et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23 (2004) 2206-2215
25. Simpson P.T., et al. Molecular evolution of breast cancer. J. Pathol. 205 (2005) 248-254
26. Slone B.F., et al. Lysosomal cathepsin B: correlation with metastatic potential. Science 212 (1981) 1151-1153
27. Song J., et al. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochem. Biophys. Res. Commun. 340 (2006) 175-182
28. Sotiropoulou G., et al. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J. Biol. Chem. 272 (1997) 903-910
29. Srivatsan E.S., et al. Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene 21 (2002) 5631-5642
30. Symmans W.F. Histopathology of breast cancer: correlation with molecular markers. In: Ross J.S., and Hortobagyi G.N. (Eds). Molecular Oncology of Breast Cancer (2005), Jones and Bartlett, Boston 106-116
31. Vigneswaran N., et al. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increase cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sci. 78 (2006) 898-907
32. Zeeuwen P.L. Epidermal differentiation: the role of proteases and their inhibitors. Eur. J. Cell Biol. 83 (2004) 761-773
33. Zeeuwen P.L., et al. Cystatin M/E expression in inflammatory and neoplastic skin disorders. Br. J. Dermatol. 147 (2002) 87-94
34. Zhang J., et al. Cystatin M: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 64 (2004) 6957-6964
35. Zhong S., et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26 (2006) 2621-2634